Phosphonicacid, P,P'-(3-amino-1-hydroxypropylidene)bis-, sodium salt (1:2) cas no:57248-88-1
Synonyms: Phosphonicacid, (3-amino-1-hydroxypropylidene)bis-, disodium salt (9CI);3-Amino-1-hydroxypropane-1,1-diphosphonicacid disodium salt;APD;Aminomux;Aredia;CGP 23339A;CGP 23339AE;Disodium3-amino-1-hydroxypropane-1,1-diphosphonate;Pamidronic acid disodium salt;
NamePhosphonicacid, P,P'-(3-amino-1-hydroxypropylidene)bis-, sodium salt (1:2)
CAS57248-88-1
SynonymsPhosphonicacid, (3-amino-1-hydroxypropylidene)bis-, disodium salt (9CI);3-Amino-1-hydroxypropane-1,1-diphosphonicacid disodium salt;APD;Aminomux;Aredia;CGP 23339A;CGP 23339AE;Disodium3-amino-1-hydroxypropane-1,1-diphosphonate;Pamidronic acid disodium salt;
EINECS(EC#)260-647-1
Molecular FormulaC3H9NNa2O7P2
Molecular Weight279.03
AppearanceWhite Crystals
storage temp2-8°C
Globally Harmonized System of Classification adn Labelling of Chemicals(GHS)
HazardclassIRRITANT
Hazard Xn:Harmful
Risk R22
Safety
Hazard Codes:?
Xn
Risk Statements: 22-48-41-37/38-20/21/22
R22:Harmful if swallowed.?
R48:Danger of serious damage to health by prolonged exposure.?
R41:Risk of serious damage to the eyes.?
R37/38:Irritating to respiratory system and skin.?
R20/21/22:Harmful by inhalation, in contact with skin and if swallowed.
Safety Statements: 22-26-36/37/39-45
S22:Do not breathe dust.?
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.?
S36/37/39:Wear suitable protective clothing, gloves and eye/face protection.?
S45:In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
WGK Germany: 3
RTECS: SZ6525000
| Organism |
Test Type |
Route |
Reported Dose (Normalized Dose) |
Effect |
Source |
| dog |
LDLo |
intravenous |
20mg/kg (20mg/kg) |
? |
Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 36, Pg. 2408, 1994. |
| man |
TDLo |
oral |
750ug/kg/5D-I (0.75mg/kg) |
SENSE ORGANS AND SPECIAL SENSES: VISUAL FIELD CHANGES: EYE
SENSE ORGANS AND SPECIAL SENSES: DIPLOPIA: EYE
SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE |
Australian and New Zealand Journal of Medicine. Vol. 24, Pg. 320, 1994. |
| mouse |
LD50 |
intraperitoneal |
190mg/kg (190mg/kg) |
? |
British UK Patent Application. Vol. #2096889, |
| mouse |
LD50 |
intravenous |
45mg/kg (45mg/kg) |
? |
British UK Patent Application. Vol. #2096889, |
| mouse |
LD50 |
oral |
625mg/kg (625mg/kg) |
? |
British UK Patent Application. Vol. #2096889, |
| rat |
LD50 |
intravenous |
50mg/kg (50mg/kg) |
? |
Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 36, Pg. 2408, 1994. |
| women |
TDLo |
intravenous |
600ug/kg/6H-C (0.6mg/kg) |
? |
Lancet. Vol. 1, Pg. 622, 1987. |
| women |
TDLo |
intravenous |
900ug/kg (0.9mg/kg) |
MUSCULOSKELETAL: JOINTS |
Annals of Pharmacotherpy. Vol. 31, Pg. 499, 1997. |
